Eight start ups created in 2015 only!
New fiber optic guide-wire will enable surgeons to perform highly accurate hip fracture and spinal fusion surgery with minimal side effects
Troublemaking’ bacteria that is a major factor in periodontitis prevents the body from properly fending off cancerous cells, Hebrew U research shows
A saliva-based pregnancy test, a blood test to predict severe health issues, and a home printer which produces complex electronic equipment.
It sounds like science fiction, but for Israeli inventors and their clients, it is an achievable to-do...
As a young physics student in the Soviet Union, Prof. Alexander Vainstein never could have imagined that one day he’d be helping people with malaria, but that’s exactly what happened – and all thanks to some colorful flowers.
In her bid for the Democratic nomination, Clinton rarely misses an opportunity to tout her record on early childhood education, from her first job out of law school at the Children’s Defense Fund to her Too Small To Fail program at The Clinton...
The Ripples technology originated at Prof. Shlomo Magdassi’s lab at the Hebrew University of Jerusalem, was licensed-out by Yissum, the technology transfer company of the Hebrew University, and was brought to market with seed funding from Landa...
CollPlant is a clinical stage regenerative Medicine Company focused on developing and commercializing tissue repair products, initially for orthobiologics and advanced wound care markets. Our products are based on our rhCollagen (recombinant...
Yissum's start up Betalin Therapeutics is developing an engineered micro-pancreas (EMP) that can sustain significant levels of glucose-regulated insulin secretion from transplanted beta cells.
They are at the heart of every electronic device. Yet the way printed circuit boards, or PCBs, are made, hasn't changed in decades. Enter Israeli startup Nano Dimension. It's looking to disrupt this 100 billion-dollar market with an all-new 3D...
Enter AB103, a rationally designed short peptide that modulates the inflammatory response by binding to the CD28 dimer interface. Ness Ziona, Israel-based Atox has just launched the phase III study called ACCUTE, a rough acronym for "AB103...